Merck Bullish On Januvia Prospects Despite Soft First Quarter Sales
This article was originally published in The Pink Sheet Daily
Executive Summary
The pharma company sees plenty of potential for its top-selling drug even as its sales came in weak during the first quarter. Meanwhile, Merck welcomes its new head of R&D and the potential for change.